BackGilead Sciences Overview

Gilead Sciences Receivables

Gilead Sciences's receivables is $4.9B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$4.94B
↓ 3.10% YoYΔ $-157.92M vs prior year quarter

Peer trimmed avg / median

Loading

Gilead Sciences Receivables History

Loading

Gilead Sciences vs. peers: Receivables Comparison

Loading

Gilead Sciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Gilead Sciences (GIS.DE) FAQ

As of the most recent data (September 2026), GIS.DE shows a receivables of $4.9B. That compares with $5.1B in the prior-year period — down 3.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GIS.DE's receivables is now $4.9B (was $5.1B) — a 3.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Gilead Sciences is outperforming or lagging.

Tracking GIS.DE's receivables over time shows whether Gilead Sciences is scaling, shrinking, or reshaping that part of the business. The current reading is $4.9B That compares with $5.1B in the prior-year period — down 3.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Gilead Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $4.9B) with ownership activity and broader fundamentals.

Gilead Sciences's receivables is $4.9B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.